Retail Employees Superannuation Pty Ltd as trustee for Retail Employees Superannuation Trust Sells 9,127 Shares of Thermo Fisher Scientific Inc. $TMO

Retail Employees Superannuation Pty Ltd as trustee for Retail Employees Superannuation Trust trimmed its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 34.8% during the third quarter, HoldingsChannel reports. The fund owned 17,118 shares of the medical research company’s stock after selling 9,127 shares during the period. Thermo Fisher Scientific comprises about 2.8% of Retail Employees Superannuation Pty Ltd as trustee for Retail Employees Superannuation Trust’s investment portfolio, making the stock its 11th largest position. Retail Employees Superannuation Pty Ltd as trustee for Retail Employees Superannuation Trust’s holdings in Thermo Fisher Scientific were worth $11,556,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds also recently made changes to their positions in the business. BlackRock Inc. acquired a new stake in shares of Thermo Fisher Scientific in the 2nd quarter valued at approximately $15,501,867,000. Corient Private Wealth LP bought a new stake in shares of Thermo Fisher Scientific during the 2nd quarter worth about $382,547,000. Bank of New York Mellon Corp acquired a new position in shares of Thermo Fisher Scientific in the second quarter valued at approximately $1,974,561,000. Bank of America Corp DE acquired a new position in Thermo Fisher Scientific in the 2nd quarter valued at $1,952,930,000. Finally, Legal & General Group Plc acquired a new position in shares of Thermo Fisher Scientific in the second quarter valued at about $1,122,351,000. 89.23% of the stock is owned by institutional investors.

Insider Buying and Selling at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, CAO Joseph Holmes sold 420 shares of the business’s stock in a transaction that occurred on Friday, August 7th. The stock was sold at an average price of $584.81, for a total transaction of $245,620.20. Following the completion of the sale, the chief accounting officer directly owned 2,966 shares of the company’s stock, valued at approximately $1,734,546.46. The trade was a 12.40% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, VP Lisa Britt sold 11,440 shares of the company’s stock in a transaction on Wednesday, August 19th. The stock was sold at an average price of $613.12, for a total value of $7,014,092.80. Following the sale, the vice president owned 14,784 shares of the company’s stock, valued at $9,064,366.08. This trade represents a 43.62% decrease in their position. The SEC filing for this sale provides additional information. In the last three months, insiders have sold 73,768 shares of company stock worth $44,122,820. 0.33% of the stock is currently owned by corporate insiders.

Thermo Fisher Scientific Price Performance

TMO stock opened at $679.48 on Tuesday. The company’s 50-day moving average is $638.93 and its 200-day moving average is $549.90. The stock has a market capitalization of $251.24 billion, a PE ratio of 28.95, a price-to-earnings-growth ratio of 2.89 and a beta of 0.87. The company has a debt-to-equity ratio of 0.74, a current ratio of 1.55 and a quick ratio of 1.18. Thermo Fisher Scientific Inc. has a 1 year low of $435.27 and a 1 year high of $704.00.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings data on Thursday, July 23rd. The medical research company reported $6.03 EPS for the quarter, beating analysts’ consensus estimates of $5.71 by $0.32. Thermo Fisher Scientific had a return on equity of 17.09% and a net margin of 15.04%. The firm had revenue of $11.99 billion during the quarter, compared to analysts’ expectations of $11.71 billion. During the same quarter last year, the firm posted $4.28 earnings per share. The company’s revenue for the quarter was up 10.5% compared to the same quarter last year. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. Equities research analysts expect that Thermo Fisher Scientific Inc. will post 25.13 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research firms have commented on TMO. HSBC upgraded Thermo Fisher Scientific from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, September 1st. Evercore set a $570.00 price objective on shares of Thermo Fisher Scientific in a research report on Monday, July 6th. CLSA started coverage on Thermo Fisher Scientific in a report on Thursday, September 3rd. They issued an “outperform” rating and a C$748.00 target price for the company. Morgan Stanley raised their price target on shares of Thermo Fisher Scientific from $650.00 to $730.00 and gave the company an “overweight” rating in a research note on Monday, October 12th. Finally, TD Cowen lifted their price objective on Thermo Fisher Scientific from $675.00 to $760.00 and gave the stock a “buy” rating in a research note on Tuesday, October 13th. Two analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating, three have issued a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $654.05.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc is a global supplier of laboratory products, analytical instruments, reagents, consumables, software and services used in scientific research, healthcare, pharmaceuticals, biotechnology and industrial applications. The company serves customers ranging from academic institutions and government agencies to hospitals, clinical laboratories and pharmaceutical manufacturers.

Its offerings include instruments and systems for genetic analysis, mass spectrometry, chromatography, electron microscopy and materials science, as well as molecular biology reagents, cell culture products, laboratory plastics and research chemicals.